Credo Diagnostics Biomedical is finalizing a rapid point-of-care molecular test for the detection of novel Coronavirus COVID-19 in 20 minutes

To date, the novel Coronavirus has killed more than 2,000 people with more than 75,000 confirmed cases worldwide.

Leveraging its real-time PCR point-of-care platform, the VitaPCRTM, which was introduced during the American Association of Clinical Chemistry Conference (AACC) in Anaheim last year, the test will deliver results in 20 minutes with a hands-on time of 1 minute. With minimal training required, the solution is ideal for the near-patient and point-of-care settings, allowing efficient and rapid triage of suspected cases of the COVID-19, even in areas with limited resources.

The advantages are:

– The 20 minutes sample to result allows rapid and efficient screening of novel Coronavirus resulting in immediate diagnosis for faster patient triage and quarantine procedures for infected individuals.

– The VitaPCR™ platform is versatile. It can be deployed without additional equipment in various clinical settings such as laboratory, ER, clinics, and even at the point-of-care or point-of-entry such as the airports and seaports.

– Combining speed and ease of use, it can immediately increase any facility testing output, reducing the over-reliance on a crowded centralized laboratory for testing as well as the risk of human errors.

– Requiring little to no training to operate; it reduces the amount of highly trained technicians required to prepare and perform the tests every day while increasing the laboratory testing capacity.

VitaPCR™ COVID-19 Assay will be available shortly while pending Emergency Use Authorization from the US FDA and Emergency Use Listing from the WHO.